Literature DB >> 20514445

AKT2 expression is associated with glioma malignant progression and required for cell survival and invasion.

Junxia Zhang1, Lei Han, Anling Zhang, Yingyi Wang, Xiao Yue, Yongping You, Peiyu Pu, Chunsheng Kang.   

Abstract

Recent data suggest that AKT2, one of AKT isoforms, plays an important role in tumorigenesis of human cancers. However, little evidence exists to show the mechanism of AKT2 involved in tumorigenesis. In this study, we show that AKT2 protein expression increased significantly in high grade gliomas in comparison to low grade gliomas and correlated with the expression of NFkappaB, BCL2, MMP2 and MMP9 by immunostaining. Further, down-regulation of AKT2 expression by antisense AKT2 induced glioma cell apoptosis mediated by NFkappaB and BCL2. In addition, decreased MMP2 and MMP9 expression in AKT2 knocked-down glioma cells was subsequently detected, consistent with the decreased invasion. These findings indicate that AKT2 expression is associated with more advanced and especially aggressive gliomas and critical for cell survival and invasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20514445     DOI: 10.3892/or_00000829

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.

Authors:  Junxia Zhang; Kai Huang; Zhendong Shi; Jian Zou; Yingyi Wang; Zhifan Jia; Anling Zhang; Lei Han; Xiao Yue; Ning Liu; Tao Jiang; Yongping You; Peiyu Pu; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

3.  MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R.

Authors:  Tianzhu Guo; Ying Feng; Qingyang Liu; Xue Yang; Tao Jiang; Yan Chen; Quangeng Zhang
Journal:  Tumour Biol       Date:  2014-08-13

4.  Nuclear translocation of β-catenin is essential for glioma cell survival.

Authors:  Zhendong Shi; Xiaomin Qian; Lanquan Li; Junxia Zhang; Shanjun Zhu; Jialin Zhu; Luyue Chen; Kailiang Zhang; Lei Han; Shizhu Yu; Peiyu Pu; Tao Jiang; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-15       Impact factor: 4.147

Review 5.  MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas.

Authors:  Yingyi Wang; Xiefeng Wang; Junxia Zhang; Guan Sun; Hui Luo; Chunsheng Kang; Peiyu Pu; Tao Jiang; Ning Liu; Yongping You
Journal:  J Neurooncol       Date:  2011-08-13       Impact factor: 4.130

6.  MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.

Authors:  Junchao Cai; JingJing Zhao; Nu Zhang; Xiaonan Xu; Rong Li; Yang Yi; Lishan Fang; Le Zhang; Mengfeng Li; Jueheng Wu; Heng Zhang
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

7.  Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis.

Authors:  Norbert Berndt; Ronil Patel; Hua Yang; Maria E Balasis; Saïd M Sebti
Journal:  Cell Cycle       Date:  2013-06-06       Impact factor: 4.534

Review 8.  Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness.

Authors:  Emmanuel Chautard; Zangbéwendé Guy Ouédraogo; Julian Biau; Pierre Verrelle
Journal:  J Neurooncol       Date:  2014-01-30       Impact factor: 4.130

9.  Astrocyte elevated gene-1 interacts with Akt isoform 2 to control glioma growth, survival, and pathogenesis.

Authors:  Bin Hu; Luni Emdad; Manny D Bacolod; Timothy P Kegelman; Xue-Ning Shen; Mohammad A Alzubi; Swadesh K Das; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2014-10-10       Impact factor: 12.701

10.  MicroRNA miR-451 downregulates the PI3K/AKT pathway through CAB39 in human glioma.

Authors:  Yuan Tian; Yang Nan; Lei Han; Anling Zhang; Guangxiu Wang; Zhifan Jia; Jianwei Hao; Peiyu Pu; Yue Zhong; Chunsheng Kang
Journal:  Int J Oncol       Date:  2011-12-15       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.